The PD-L1/4-1BB Bispecific Antibody–Anticalin Fusion Protein PRS-344/S095012 Elicits Strong T-Cell Stimulation in a Tumor-Localized Manner

PURPOSE: While patients responding to checkpoint blockade often achieve remarkable clinical responses, there is still significant unmet need due to resistant or refractory tumors. A combination of checkpoint blockade with further T-cell stimulation mediated by 4-1BB agonism may increase response rat...

Descripción completa

Detalles Bibliográficos
Autores principales: Peper-Gabriel, Janet K., Pavlidou, Marina, Pattarini, Lucia, Morales-Kastresana, Aizea, Jaquin, Thomas J., Gallou, Catherine, Hansbauer, Eva-Maria, Richter, Marleen, Lelievre, Helene, Scholer-Dahirel, Alix, Bossenmaier, Birgit, Sancerne, Celine, Riviere, Matthieu, Grandclaudon, Maximilien, Zettl, Markus, Bel Aiba, Rachida S., Rothe, Christine, Blanc, Veronique, Olwill, Shane A.
Formato: Online Artículo Texto
Lenguaje:English
Publicado: American Association for Cancer Research 2022
Materias:
Translational Cancer Mechanisms and Therapy
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9662934/
https://www.ncbi.nlm.nih.gov/pubmed/35121624
http://dx.doi.org/10.1158/1078-0432.CCR-21-2762

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9662934/
https://www.ncbi.nlm.nih.gov/pubmed/35121624
http://dx.doi.org/10.1158/1078-0432.CCR-21-2762

Ejemplares similares